These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 23505633)

  • 1. Organometallic anticancer complexes of lapachol: metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity.
    Kandioller W; Balsano E; Meier SM; Jungwirth U; Göschl S; Roller A; Jakupec MA; Berger W; Keppler BK; Hartinger CG
    Chem Commun (Camb); 2013 Apr; 49(32):3348-50. PubMed ID: 23505633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the antitumor properties of novel cyclometalated benzimidazole Ru(II), Ir(III) and Rh(III) complexes.
    Yellol GS; Donaire A; Yellol JG; Vasylyeva V; Janiak C; Ruiz J
    Chem Commun (Camb); 2013 Dec; 49(98):11533-5. PubMed ID: 24177492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological properties of novel ruthenium- and osmium-nitrosyl complexes with azole heterocycles.
    Novak MS; Büchel GE; Keppler BK; Jakupec MA
    J Biol Inorg Chem; 2016 Jun; 21(3):347-56. PubMed ID: 26961253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruthenium(II) and osmium(II) 1,2,3-triazolylidene organometallics: a preliminary investigation into the biological activity of 'click' carbene complexes.
    Kilpin KJ; Crot S; Riedel T; Kitchen JA; Dyson PJ
    Dalton Trans; 2014 Jan; 43(3):1443-8. PubMed ID: 24201979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactive Oxygen Species Production Is Responsible for Antineoplastic Activity of Osmium, Ruthenium, Iridium and Rhodium Half-Sandwich Type Complexes with Bidentate Glycosyl Heterocyclic Ligands in Various Cancer Cell Models.
    Kacsir I; Sipos A; Bényei A; Janka E; Buglyó P; Somsák L; Bai P; Bokor É
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, structure and anticancer properties of new biotin- and morpholine-functionalized ruthenium and osmium half-sandwich complexes.
    Marloye M; Inam H; Moore CJ; Debaille V; Pritchard JR; Gelbcke M; Meyer F; Dufrasne F; Berger G
    J Biol Inorg Chem; 2021 Aug; 26(5):535-549. PubMed ID: 34173882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes.
    van Rijt SH; Hebden AJ; Amaresekera T; Deeth RJ; Clarkson GJ; Parsons S; McGowan PC; Sadler PJ
    J Med Chem; 2009 Dec; 52(23):7753-64. PubMed ID: 19791745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates.
    Riedl CA; Flocke LS; Hejl M; Roller A; Klose MH; Jakupec MA; Kandioller W; Keppler BK
    Inorg Chem; 2017 Jan; 56(1):528-541. PubMed ID: 27996251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor pentamethylcyclopentadienyl rhodium complexes of maltol and allomaltol: synthesis, solution speciation and bioactivity.
    Dömötör O; Aicher S; Schmidlehner M; Novak MS; Roller A; Jakupec MA; Kandioller W; Hartinger CG; Keppler BK; Enyedy ÉA
    J Inorg Biochem; 2014 May; 134():57-65. PubMed ID: 24556426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards targeting anticancer drugs: ruthenium(ii)-arene complexes with biologically active naphthoquinone-derived ligand systems.
    Kubanik M; Kandioller W; Kim K; Anderson RF; Klapproth E; Jakupec MA; Roller A; Söhnel T; Keppler BK; Hartinger CG
    Dalton Trans; 2016 Aug; 45(33):13091-103. PubMed ID: 27214822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative solution equilibrium studies of antitumor ruthenium(η
    Dömötör O; Pape VFS; May NV; Szakács G; Enyedy ÉA
    Dalton Trans; 2017 Mar; 46(13):4382-4396. PubMed ID: 28287667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells.
    Pracharova J; Novohradsky V; Kostrhunova H; Štarha P; Trávníček Z; Kasparkova J; Brabec V
    Dalton Trans; 2018 Sep; 47(35):12197-12208. PubMed ID: 30112527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly Cytotoxic Osmium(II) Compounds and Their Ruthenium(II) Analogues Targeting Ovarian Carcinoma Cell Lines and Evading Cisplatin Resistance Mechanisms.
    Hildebrandt J; Häfner N; Kritsch D; Görls H; Dürst M; Runnebaum IB; Weigand W
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiparasitic activities of novel ruthenium/lapachol complexes.
    Barbosa MI; Corrêa RS; de Oliveira KM; Rodrigues C; Ellena J; Nascimento OR; Rocha VP; Nonato FR; Macedo TS; Barbosa-Filho JM; Soares MB; Batista AA
    J Inorg Biochem; 2014 Jul; 136():33-9. PubMed ID: 24727183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lapachol in the Design of a New Ruthenium(II)-Diphosphine Complex as a Promising Anticancer Metallodrug.
    Oliveira KM; Honorato J; Demidoff FC; Schultz MS; Netto CD; Cominetti MR; Correa RS; Batista AA
    J Inorg Biochem; 2021 Jan; 214():111289. PubMed ID: 33137682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi-target caffeine derived rhodium(i) N-heterocyclic carbene complex: evaluation of the mechanism of action.
    Zhang JJ; Muenzner JK; Abu El Maaty MA; Karge B; Schobert R; Wölfl S; Ott I
    Dalton Trans; 2016 Aug; 45(33):13161-8. PubMed ID: 27334935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. cis-Tetrachlorido-bis(indazole)osmium(iv) and its osmium(iii) analogues: paving the way towards the cis-isomer of the ruthenium anticancer drugs KP1019 and/or NKP1339.
    Büchel GE; Kossatz S; Sadique A; Rapta P; Zalibera M; Bucinsky L; Komorovsky S; Telser J; Eppinger J; Reiner T; Arion VB
    Dalton Trans; 2017 Sep; 46(35):11925-11941. PubMed ID: 28850133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein-binding, cytotoxicity in vitro and cell cycle arrest of ruthenium(II) polypyridyl complexes.
    Liu SH; Zhu JW; Xu HH; Wang Y; Liu YM; Liang JB; Zhang GQ; Cao DH; Lin YY; Wu Y; Guo QF
    Spectrochim Acta A Mol Biomol Spectrosc; 2016 May; 161():77-82. PubMed ID: 26956530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strained ruthenium complexes are potent light-activated anticancer agents.
    Howerton BS; Heidary DK; Glazer EC
    J Am Chem Soc; 2012 May; 134(20):8324-7. PubMed ID: 22553960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences.
    Hanif M; Nazarov AA; Hartinger CG; Kandioller W; Jakupec MA; Arion VB; Dyson PJ; Keppler BK
    Dalton Trans; 2010 Aug; 39(31):7345-52. PubMed ID: 20601976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.